Once we confirmed the efficacy of silencing WT1 as a mechanism to diminish the malignancy phenotype in vitro, we wanted to further expand the application of this siRNA therapy on an animal model bearing melanoma metastases on the lungs. The gene discussed is WT1; the disease is melanoma.